3Schett G,Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis[J]. Ann Rheum Dis, 2008,67 (7) : 909-916.
4Mavropoulos A, Orfanidou T, Liaskos C, et al. p38 mitogen-activated pro- tein kinase (p38 MAPK)-mediated autoimmunity:lessons to learn from ANCA vasculitis and pemphigus vulgaris[J]. Autoimmun Rev,2013,12 (5) :580-590.
5Patterson H, Nibbs R, Meinnes I, et al. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases[J]. Clin Exp Immunol, 2014,176(1 ):1-10.
6Han J, Lee JD, Bibhs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells[J]. Science, 1994,265 (5173) : 808-811.
7Ferreiro I, Joaquin M, Islam A, et al. Whole genome analysis of p38 SAPK- mediated gene expression upon stress[J]. BMC Genomics, 2010,11:144.
8Terajima M ,Inoue T, Magari K, et al. Anti-inflammatory effect and selec- tivity profile of AS1940477,a novel and potent p38 mitogen-activated protein kinase inhibitor[J]. Eur J Pharmacol, 2013,698 ( 1/2/3 ) :455-462.
9Simmons DL. Targeting kinases:a new approach to treating inflammatory rheumatic diseases[J]. Curr Opin Pharmacol, 2013,13 (3):426-434.
10Cuadrado A,Nebreda AR. Mechanisms and functions of p38 MAPK sig- nalling[J]. Biochem J, 2010,429 ( 3 ) : 403-417.
3Fischer A, Brown KK.Interstitial lung disease in undifferen- tiated forms of connective tissue disease [ J ]. Arthritis Care Res ( Hoboken), 2014.Epub ahead of print.
4Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor- related protein ST2 and induces T helper type 2-associated cytokines [ J ].Immunity, 2005, 23 (5) :479-490.
5Girard JP. A direct inhibitor of HMGB1 cytokine[ J] .Chem- Biol, 2007, 14(4) :345-347.
6Ameh FC, Edworth SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifi- cation of rheumatoid arthritis [ J ]. Arthritis Rheum, 1988,31 (5) :315-324.
7Demedts M, Costabel U.ArpS/ERS international muhidiscipli- nary consensus classification of the idiopathic international pneumonias[ J] .Eur Respir J,2002,19( 11 ) :794-796.
8Sanada S, Hakuno D, Hiqqins LJ, et al.IL-33 and ST2 com- prise a critical biomechanically induced and cardioprotective signaling system [ J] .Clin Invest, 2007,117 (6) :1538-1549.
9Ali S, Huber M, Kollewe C, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lympho- cytes and mast cells [ J ]. Proc Natl Acad Sci USA, 2007, 104(47) : 18660-18665.
10Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker[ J]. Nat Rev Drug Discov, 2008,7(10) :827-840.
6blulIer - Ladner U, Gay RE, Gay S. Activation of synovioeytes [J]. Curr Opin Rheumatol, 2000, 12(3) : 186 - 194.
7Yamanishi Y, Boyle DL, Green DR, et al. p53 tumor suppressor gene mutations in (ibrohlast - like synovioeytes from erosion syno- vium and nonerosion synovium in rheumatoid arthritis [ J ]. Arthri- tis Res Ther, 2005, 7(1) : R12 -R18.
8Matsumoto S, MUller- Ladner U, Gay RE, et al. Ultrastructural demonstration of apoptosis, Fas and Bcl - 2 expression of rheuma- toid synovial fibroblasts [ J ]. J Rheumatol, 1996, 23 ( 8 ) : 1345 - 1352.
9Georganas C, Liu H, Perlman H, et al. Regulation of IL - 6 and IL- 8 expression in rheumatoid arthritis syovial fibroblasts: the dominant role for NF - kappa B but not C/EBP beta or c - Jun [J]. J Immuuol, 2000, 165(12) : 7199 -7206.
10Miagkov AV, Kovalenko DV, Brown CE, et al. NF - kappa B ac- tivation provides the potential link between inflammation and hy- perplasia in the arthritic joint [ J ]. Proc Natl Acad Sci U S A, 1998, 95(23) : 13859 - 13864.
